# A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

> **NCT06161441** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 195 (actual)

## Conditions studied

- Resectable Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Fianlimab
- **DRUG:** Cemiplimab
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06161441
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-16
- **Primary completion:** 2026-04-17
- **Final completion:** 2029-11-04
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161441, "A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06161441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*